Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01685567
Other study ID # SRM-2012-02
Secondary ID
Status Completed
Phase Phase 3
First received September 10, 2012
Last updated December 16, 2016
Start date November 2012
Est. completion date July 2016

Study information

Verified date December 2016
Source Silk Road Medical
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of the MICHI™ Neuroprotection System with Filter (MICHI™ NPS+f) in providing cerebral embolic protection during carotid artery stenting. It will be used in conjunction with a FDA approved carotid artery stent for the treatment of carotid artery disease.


Description:

Cerebral embolization during carotid artery stenting (CAS) can often precipitate severe adverse neurological effects. Most major clinical studies of CAS have used distal filters for cerebral protection and have compared the neurologic complication rates with those of carotid endarterectomy (CEA). Many currently available embolic protection devices, however, have limited efficacy in capturing microembolic debris that is liberated during stenting, pre-dilatation and post-dilatation. Distal protection systems are furthermore limited by the need to cross the lesion prior to deployment. Some studies have shown a relatively high incidence of cerebral infarction even when distal protection devices are employed.

Cerebral protection with carotid flow reversal is a method that was developed as an alternative to the use of distal protection devices. While novel in its approach, this method too has its limitations. Another technique developed employs carotid flow reversal prior to traversing the stenosis and can be accomplished by directly accessing the carotid anatomy without the use of the transfemoral approach. Major benefits to this method include a simpler route to the target lesion and the ability to perform the procedure on patients with severe carotid tortuosity and difficult aortic arch anatomy.


Recruitment information / eligibility

Status Completed
Enrollment 286
Est. completion date July 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient must meet one of the following criteria regarding neurological symptom status and degree of stenosis:

- Symptomatic: Stenosis must be greater than or equal to 50% as determined by angiogram and the patient has a history of stroke (minor or non-disabling), TIA and/or amaurosis fugax within 180 days of the procedure.

- Asymptomatic: Stenosis must be greater than or equal to 70% as determined by angiogram without any neurological symptoms within the prior 180 days.

2. Target vessel must meet diameter requirements for stent (refer to selected stent IFU for diameter requirements).

3. Patient has a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA).

4. Patient is >18 years of age.

5. Patient has no childbearing potential or has a negative pregnancy test within one week prior to the study procedure.

6. Patient (or their legal guardian) understands the nature of the procedure and has provided a signed informed consent using a form that has been reviewed and approved by the Investigational Review Board/Ethics Committee of the respective clinical site prior to the procedure. This will be obtained prior to participation in the study.

7. Patient is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluations.

8. Patient meets at least one surgical high-risk criteria.

Exclusion Criteria:

1. Chronic atrial fibrillation, any episode of paroxysmal atrial fibrillation within the past 6 months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation.

2. Evolving stroke, severe dementia, intracranial tumor, history of spontaneous intracranial hemorrhage within the past 12 months, recent stroke of sufficient size, hemorrhagic transformation of an ischemic stroke within the past 60 days, history of major stroke with major neurological deficit.

3. Active bleeding diathesis or coagulopathy or will refuse blood transfusion.

4. Had or will have CABG, endovascular stent procedure, valve intervention or vascular surgery within 30 days before or after the intervention.

5. Recently (<60 days prior to procedure) implanted heart valve (either surgically or endovascularly), which is a known source of emboli as confirmed on echocardiogram.

6. Recent GI bleed that would interfere with antiplatelet therapy.

7. Life expectance of < 12 months post procedure.

8. History of intolerance or allergic reaction to any of the study medications or stent materials.

9. Myocardial Infarction within 72 hours prior to the intervention.

10. Has had neurologic illnesses within the past two years characterized by fleeting or fixed neurologic deficit which cannot be distinguished from TIA or stroke.

11. Has Hgb <10 g/dl, platelet count <125,000/µl, uncorrected INR >1.5, bleeding time >1 minute beyond upper limit normal, or heparin-associated thrombocytopenia.

12. Occlusion or (TIMI 0) "string sign" >1cm of the ipsilateral common or internal carotid artery.

13. Has vertebrobasilar insufficiency symptoms only, without clearly identifiable symptoms referable to the study carotid artery.

14. Knowledge of cardiac sources of emboli, Ostium of Common Carotid Artery (CCA) requires revascularization.

15. Presence of extensive or diffuse atherosclerotic disease involving the proximal common carotid artery that would preclude the safe introduction of the study device.

16. Has less than 5cm between the clavicle and bifurcation.

17. Bilateral carotid stenosis if intervention is planned within the 30-day of the index procedure.

18. An intraluminal filling defect that is not associated with an ulcerated target lesion.

19. Abnormal angiographic findings.

20. Previous intervention in the ipsilateral proximal CCA or previous placed intravascular stent in target vessel

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
MICHI NPS+f
Cerebral protection with carotid flow reversal

Locations

Country Name City State
Spain Hospital Virgen de la Salud Toledo
United States Albany Medical Center Albany New York
United States University of Michigan Medical Center Ann Arbor Michigan
United States Cardiothoracic & Vascular Surgeons Austin Texas
United States Johns Hopkins Bayview Medical Center Baltimore Maryland
United States Massachusetts General Hospital Boston Massachusetts
United States University at Buffalo Neurosurgery, Inc Buffalo New York
United States Cleveland Clinic Foundation Cleveland Ohio
United States University Hospitals Case Medical Center and Case Western Reserve University School of Medicine Cleveland Ohio
United States Riverside Methodist Hospital Columbus Ohio
United States Dallas VA Medical Center Dallas Texas
United States Methodist Medical Center Dallas Texas
United States McLaren Regional Medical Center Flint Michigan
United States Greenville Hospital System Greenville South Carolina
United States Peter Morton UCLA Medical Center Los Angeles California
United States Columbia University New York New York
United States Sentara Vascular Specialists Norfolk Virginia
United States Oklahoma Heart Oklahoma City Oklahoma
United States Florida Hospital Orlando Florida
United States Washington University School of Medicine St. Louis Missouri
United States Jobst Vascular Institute Toledo Ohio

Sponsors (1)

Lead Sponsor Collaborator
Silk Road Medical

Countries where clinical trial is conducted

United States,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stroke, Myocardial Infarction, and Death The primary endpoint for overall evaluation of the study is a composite endpoint consisting of the first occurrence of any of the following major adverse events within 30 days. 30 days post procedure Yes
Secondary Technical Success The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. 0 to 30 days No
Secondary Acute Device Success The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. 0 to 30 days No
Secondary Procedural Success The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. 0 to 30 days No
Secondary Access Site Complications The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. 0 to 30 days No
Secondary Contrast Usage The analyses to be conducted on the secondary endpoints are intended to provide additional supportive evidence of the efficacy and safety of the device. 0 to 30 days No
Secondary Ipsilateral Stroke Data on ipsilateral stroke 31-365 days post procedure will be collected to provide additional supportive evidence of the safety of the device. 31-365 days No
See also
  Status Clinical Trial Phase
Recruiting NCT02124928 - Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis N/A
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A
Completed NCT00744523 - Proximal Protection With The Mo.Ma Device During Carotid Stenting N/A
Completed NCT00231231 - Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS) Phase 3
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Completed NCT00587717 - The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue N/A
Completed NCT02536378 - POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
Completed NCT02126982 - Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence
Active, not recruiting NCT01445613 - Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy N/A
Terminated NCT01414387 - Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting N/A
Completed NCT00406055 - CHOICE: Carotid Stenting For High Surgical-Risk Patients Phase 4
Completed NCT00403078 - SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
Terminated NCT01968226 - TRACER RGD-K5 Carotid Plaque Imaging Study Phase 2
Completed NCT00402740 - Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT) N/A
Completed NCT00287508 - Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study) Phase 4
Completed NCT00178672 - A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease Phase 4
Recruiting NCT02850588 - SVS VQI TransCarotid Revascularization Surveillance Project
Completed NCT02759653 - Norwegian Carotid Plaque Study
Withdrawn NCT01042912 - Frequency Analysis of Carotid Artery Disease N/A
Completed NCT00530504 - Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study N/A